Insights Into Pharmacoeconomics, Emerging Therapies, and Adherence
Jointly Sponsored by Albert Einstein College of Medicine, Montefiore Medical Center, The University of Tennessee College of Pharmacy, and ASiM.

Supported by an educational grant from Biogen IDEC.
Goal
To provide managed care healthcare professionals with up-to-date information regarding their role in managing patients with multiple sclerosis.

Intended Audience
This activity is designed for managed care healthcare professionals. No prerequisites required.

Learning Objectives
Albert Einstein College of Medicine and The University of Tennessee College of Pharmacy take responsibility for the content, quality, and scientific integrity of this CME/CPE activity. At the conclusion of this activity, the participant should be able to:
Discuss the impact of pharmaco- and socioeconomic issues associated with current and emerging multiple sclerosis (MS) therapies as it relates to the disease burden.
Define what constitutes optimal utilization of MS therapies and patient adherence to disease-modifying agents.
Evaluate the safety and efficacy of emerging therapies to currently available disease-modifying agents for reducing disability and relapse rate.
Discuss emerging therapies and their potential place in therapy.

Accreditation Statements
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint sponsorship of Albert Einstein College of Medicine of Yeshiva University, Montefiore Medical Center, The University of Tennessee College of Pharmacy, and ASiM. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education to provide continuing education for pharmacists.
Credit Designation Statements
Albert Einstein College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.  Successful completion of this knowledge-based educational activity will provide a statement for 1.0 contact hours credit (0.1 CEUs) and will be available for download following successful completion of the activity.  Successful completion includes participating in the activity, completing a self-assessment instrument with a score of at least 70%, and completing an evaluation instrument. If you score less than 70% on the self-assessment instrument, you will be allowed to complete the examination two more times.  ACPE Program 0064-0000-11-213-H01-P.

This continuing pharmacy education activity was produced under the supervision of Glen E. Farr, PharmD, Associate Dean for Continuing Pharmacy Education, University of Tennessee College of Pharmacy.

The estimated time to complete this educational activity: 1 hour.

Release date: March 20, 2012; Expiration date: March 20, 2013.

A participant, sponsor, faculty member, or other individual wanting to file a grievance with respect to any aspect of an activity sponsored or cosponsored by The University of Tennessee College of Pharmacy may contact the Associate Dean for Continuing Education in writing at gfarr@utasip.com. The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.

There is no fee for this educational activity.

System Requirements Windows®7, Vista, XP, 2003 Server or 2000 Mac OS®; X 10.4.11 (Tiger®) or newer

Full Disclosure Policy Affecting CME/CPE Activities:
The "Conflict of Interest Disclosure Policy" of Albert Einstein College of Medicine requires that faculty participating in any CME activity disclose to the audience any relationship(s) with a pharmaceutical, product, or device company. Any presenter whose disclosed relationships prove to create a conflict of interest with regard to their contribution to the activity will not be permitted to present. The Albert Einstein College of Medicine also requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

The staff of CCME of Albert Einstein College of Medicine have no disclosures to report with commercial interests other than the following:
Steven Jay Feld or a member of his household owns securities in: Bioheart, Inc, Chelsea Therapeutics, Inc, and Pharmacopeia, Inc.

As an accredited provider by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of The University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Course Director and Participating Faculty reported the following:

COURSE DIRECTOR
Sheldon J. Rich, RPh, PhD
President – SJR Associates, LLC
Palm Beach Gardens, Florida
Adjunct Clinical Assistant Professor
University of Michigan
Adjunct Assistant Professor
Wayne State University
Detroit, Michigan
Dr Rich reports serving as an advisory board moderator for Astellas Pharma US, Inc, Gilead Sciences, GlaxoSmithKline, and Teva Neuroscience; serving as an advisory board participant for Acorda Therapeutics; and serving as an expert witness for Rutledge, Manion, Rabaut, Terry & Thomas.

PARTICIPATING FACULTY
Jeffrey Bennett, MD, PhD
Professor
Departments of Neurology and Ophthalmology
University of Colorado Denver
Denver, Colorado
Dr Bennett reports serving as a consultant for Biogen Idec, EMD Serono, Inc, and Teva Neuroscience.

Gary Birnbaum, MD
Director
Multiple Sclerosis Treatment and Research Center
Clinical Professor of Neurology
University of Minnesota School of Medicine
Minneapolis, Minnesota
Dr Birnbaum reports receiving grants/research support from Biogen IDEC; serving as a consultant for Serono and Teva Neuroscience; and having other relationships with Pfizer Inc, Serono, and Teva Neuroscience.

William J. Cardarelli, PharmD
Director of Pharmacy Revenue and Supply
Pharmacy Administration
Atrius Health and Harvard Vanguard Medical Associates
Boston, Massachusetts
Dr Cardarelli reports having no relevant financial or advisory relationships with corporate organizations related to this activity.

David L. Clark, RPh, MBA
President
VisumRx
Tualatin, Oregon
Mr Clark reports being an employee of RegeneRx; being an employee and owner of VisumRx; and serving as a speaker for CBI.

Dan Curran, RPh, MBA
Pharmacy Manager
Blue Cross and Blue Shield of Rhode Island
Providence, Rhode Island
Mr Curran reports serving as an advisory board participant for PharmaStrat and SJR Associates; and serving as a survey participant for Health Strategies and Managed Care Network/Xcenda.

Richard Faris, PhD, RPh
Vice President and National Practice Leader, Rare and Specialty Therapeutics
Accredo Health
Health Outcomes Solutions
Memphis, Tennessee
Dr Faris reports holding stock in Medco Health Solutions.

Maria Lopes, MD, MS
Chief Medical Officer
AMC Health
Cresskill, New Jersey
Dr Lopes reports serving as a consultant/ad board member for Biogen IDEC.

Joseph M. Sinopoli, RPh
President

PreLaunch Strategy, LLC
Boston, Massachusetts
Mr Sinopoli reports serving as a consultant for AstraZeneca, Boehringer Ingelheim, Novo Nordisk, and Purdue Pharma, LLP.

Gary J. Tereso, PharmD
Director of Pharmacy Services
Health New England
Springfield, Massachusetts
Dr Tereso reports holding stock in Pfizer Inc and Vertex Pharmaceuticals, Inc.

Rene Elkin, MD (Reviewer)
Attending Neurologist
Bronx-Lebanon Hospital Center
Assistant Professor
The Saul R. Korey Department of Neurology
Albert Einstein College of Medicine
Bronx, New York
Dr Elkin reports serving as a consultant for Bayer, Biogen IDEC, Pfizer Inc, and Teva; holding stock in Pfizer Inc; and serving on the speakers' bureau for Bayer, Biogen IDEC, and Teva.

Patricia Gellasch, MSN, APN-C (Medical Director)
Visiting Clinical Associate in the The College of Nursing
Rutgers, The State University of NJ
New Brunswick, New Jersey
Ms Gellasch reports having no relevant financial or advisory relationships with corporate organizations related to this activity.

Notice: In accordance with ACPE Criteria for Quality, the audience is advised that authors in this CPE activity may include reference(s) to unlabeled, unapproved, or investigational uses of therapeutic agents or biomedical devices. The authors will inform the reader of when they discuss or reference an unapproved, unlabeled, or investigational use of therapeutic agent or biomedical device.

Disclaimer
The opinions expressed herein are those of the authors and do not necessarily represent the views of the Albert Einstein College of Medicine or The University of Tennessee College of Pharmacy. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

Continue
Jointly Sponsored by Albert Einstein College of Medicine, Montefiore Medical Center, The University of Tennessee College of Pharmacy, and ASiM.
Copyright © 2012 ASiM. All rights reserved.